There is paucity of research on late effects and long-term quality of life and symptom burden in patients with acute myeloid leukemia (AML).
There is a long-standing collaboration between the Italian Group for Adult Hematologic Diseases (GIMEMA) and the EORTC leukemia group in AML research and in 2015 both institutions launched a large project to update clinical and vital status of patients previously enrolled in three large international EORTC-GIMEMA randomized controlled trial (RCTs): AML-8A, AML-10 and AML-12. With the project, we aim to maximize joint efforts and take advantage of an already and well-established active international network of Investigators, to eventually gather unique knowledge on survivorship issues in AML patients treated both in RCTs and in routine care settings.
36 European Centers joined the study; 27, between Italian and non-Italian Centers, are already active and opened to patient enrollment.
Complete all sites activation and Patient accrual
All those interested in collaboration might want to contact the PI.
Prof. Fabio Efficace
Head, Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA) Data Center, Rome, Italy.
E-mail: email@example.com Tel: +39 06 441639831
This study will investigate patient-reported outcomes, such as quality of life (QoL), in long-term AML survivors.
It will include a large group of patients who received diagnosis of AML and survived at least 3 years from diagnosis. All participants will be invited to participate through their hematologist and will be asked to complete a questionnaire.